Search Results 11-20 of 16706 for Certolizumab

1. Treatment response and management of biologics in patients with ECD - Mayo Clinic

   These include tumor necrosis factor-alpha (TNFα) inhibitors (certolizumab, infliximab, adalimumab), anti-integrin agents (vedolizumab, natalizumab), and ...

2. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

   ... certolizumab pegol [≥ 400 mg]). Inadequate secondary non-response: Initially responded to induction therapy with infliximab (≥ 5 mg/kg) or adalimumab ...

3. A Study to Evaluate Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis - Mayo Clinic

   ... certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, tofacitinib, rituximab, or anakinra. Contraindications to contrast ...

4. Baricitinib (oral route) - Side effects & dosage - Mayo Clinic

   Certolizumab Pegol; Cholera Vaccine, Live; Dengue Tetravalent Vaccine, Live; Etanercept; Fedratinib; Fexinidazole; Gemfibrozil; Golimumab; Guselkumab ...

5. Drugs and Supplements that Start with C - Mayo Clinic

   Certolizumab (subcutaneous route). Cerubidine. Also known as. Daunorubicin (intravenous route). Cervarix. Also known as. Human papillomavirus vaccine ...

6. Abatacept (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

   Do not take other medicines for arthritis unless you have talked to your doctor. This includes adalimumab (Humira®), anakinra (Kineret®), certolizumab (Cimzia®) ...

7. A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

   Infliximab, certolizumab, golimumab, ABA or adalimumab within ≤ 8 weeks; Anakinra within ≤ 1 week. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO ...

8. A Study to Evaluate Remicade (Infliximab) for the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection and are at an Increased Risk of Recurrence - Mayo Clinic

   ... certolizumab. Must undergo screening for HBV; Baseline CDAI < 200; Has adequate blood and liver test values. Exclusion Criteria. Has a history of latent or ...

9. A Study Of Efficacy And Safety Of Mongersen (GED-0301) For The Treatment Of Adult And Adolescent Subjects With Active Crohn's Disease - Mayo Clinic

   ... certolizumab, or vedolizumab). Exclusion Criteria: • The presence of any of the following will exclude a subject from enrollment: Diagnosis of ulcerative ...

10. Psoriatic arthritis - Diagnosis & treatment - Mayo Clinic

    These newer drugs target specific parts of the immune system that cause joint inflammation. The medicines include adalimumab (Humira), certolizumab (Cimzia), ...